Abstract IA23: Therapeutic approaches for ARID1A-mutated ovarian cancer

Abstract

Abstract Ovarian cancer remains the most lethal gynecologic malignancy in the developed world. Despite the unprecedented progress in understanding the genetics of ovarian cancer, cures remain elusive due to a lack of insight into the mechanisms that can be targeted to develop new therapies. SWI/SNF chromatin remodeling complexes are genetically altered in ~20% of all human cancers. SWI/SNF alterations vary in different histologic subtypes of ovarian cancer, with ARID1A mutation occurring in ~50% of ovarian clear-cell carcinomas. Given the prevalence of ARID1A mutation, ovarian cancer represents a paradigm for investigating the molecular basis and exploring therapeutic strategies for SWI/SNF alterations. The presentation will discuss our recent efforts in understanding SWI/SNF alterations in ovarian cancer and specifically focuses on ARID1A mutation in endometriosis-associated clear cell and endometrioid histologic subtypes of ovarian cancer. Understanding the molecular underpinning of ARID1A mutation in ovarian cancer will provide mechanistic insights into how ARID1A inactivation contributes to ovarian cancer. In addition, how these newly gained insights can be leveraged to develop urgently needed therapeutic strategies in a personalized manner for ovarian cancer will be discussed. Citation Format: Rugang Zhang. Therapeutic approaches for ARID1A-mutated ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr IA23.